Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis

Author： Wakata N.   Saito T.   Tanaka S.   Hirano T.   Oka K.  

Publisher： Elsevier

ISSN： 0303-8467

Source： Clinical Neurology and Neurosurgery, Vol.106, Iss.1, 2003-12, pp. : 5-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Myasthenic crisis after the cessation of FK506 in a patient with myasthenia gravis

By Konishi Tetsuro   Sanada Mitsuru   Takehana Kazuya  

Journal of Neurology, Vol. 251, Iss. 9, 2004-09 ,pp. : 1154-1155

Springer Publishing Company

Access to resources Recommend Favorite

Advances in the treatment of myasthenia gravis

By Gilhus Nils Erik  

Future Neurology, Vol. 7, Iss. 6, 2012-11 ,pp. : 701-708

Future Medicine

Access to resources Recommend Favorite

Thymectomy: role in the treatment of myasthenia gravis

By Spillane J.   Hayward M.   Hirsch N.   Taylor C.   Kullmann D.   Howard R.  

Journal of Neurology, Vol. 260, Iss. 7, 2013-07 ,pp. : 1798-1801

Springer Publishing Company

Access to resources Recommend Favorite

myasthenia gravis

By  

PRACTICAL NEUROLOGY, Vol. 3, Iss. 3, 2003-06 ,pp. : 184-185

John Wiley & Sons Inc

Access to resources Recommend Favorite

Neuroprotective effect of immunosuppressant FK506 in transient focal ischemia in rats: Therapeutic time window for FK506 in transient focal ischemia

By Arii Takako   Kamiya Tatsushi   Arii Kazumasa   Ueda Masayuki   Nito Chikako   Katsura Ken-Ichiro   Katayama Yasuo  

Neurological Research, Vol. 23, Iss. 7, 2001-10 ,pp. : 755-760

Maney Publishing

Access to resources Recommend Favorite